Dr. Toni Choueiri on Cabozantinib and Nivolumab Combination in Kidney Cancer

Toni K. Choueiri, MD
Published: Tuesday, Nov 03, 2015



Toni Choueiri, MD, Dana-Farber Cancer, Clinical Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Dana Farber Cancer, discusses the potential for combination treatments in kidney cancer.

Instead of determining sequencing for cabozantinib and nivolumab, research should be focused on determining how to use the two agents in combination, says Choueiri.

While safety issues will have to be considered, the two drugs together have promise, Choueiri adds.

There is an early National Cancer Institute study going on combining cabozantinib and nivolumab. Safety results are expected soon.
 


Toni Choueiri, MD, Dana-Farber Cancer, Clinical Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Dana Farber Cancer, discusses the potential for combination treatments in kidney cancer.

Instead of determining sequencing for cabozantinib and nivolumab, research should be focused on determining how to use the two agents in combination, says Choueiri.

While safety issues will have to be considered, the two drugs together have promise, Choueiri adds.

There is an early National Cancer Institute study going on combining cabozantinib and nivolumab. Safety results are expected soon.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x